<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<META NAME="ROBOTS" CONTENT="NOINDEX, NOFOLLOW, NOARCHIVE">
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<title>Minister of Health and Long Term Care (Ontario) v. Apotex Inc. (September 16, 2005)</title>
<style><!--
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:15.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-font-kerning:0pt;
	font-weight:normal;}
h2
	{mso-style-next:Normal;
	text-align:center;
	line-height:200%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:15.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-bidi-font-weight:normal;}
h3
	{mso-style-next:Normal;
	text-align:justify;
	mso-pagination:widow-orphan;
	mso-outline-level:3;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-bidi-font-weight:normal;}
h4
	{mso-style-next:Normal;
	text-align:justify;
	line-height:200%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:EN-US;
	mso-bidi-font-weight:normal;}
h5
	{mso-style-next:Normal;
	text-align:right;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:5;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-bidi-font-weight:normal;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{text-align:justify;
	mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{text-align:justify;
	mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{text-align:justify;
	mso-pagination:widow-orphan;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{line-height:200%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{line-height:200%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:13.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;
	font-weight:bold;}
p.Doubleindent-quote, li.Doubleindent-quote, div.Doubleindent-quote
	{mso-style-name:"Double indent-quote";
	text-align:justify;
	mso-pagination:widow-orphan;
	tab-stops:1.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.Double-indent-subquote, li.Double-indent-subquote, div.Double-indent-subquote
	{mso-style-name:Double-indent-subquote;
	mso-style-parent:"";
	text-align:justify;
	mso-pagination:none;
	tab-stops:2.0in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.headingNUMBER, li.headingNUMBER, div.headingNUMBER
	{mso-style-name:"heading\: NUMBER";
	mso-style-update:auto;
	text-align:justify;
	text-indent:0in;
	line-height:200%;
	mso-pagination:widow-orphan;
	mso-list:l5 level2 lfo70;
	tab-stops:.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.ParaNO, li.ParaNO, div.ParaNO
	{mso-style-name:"Para NO \#";
	mso-style-parent:"heading\: NUMBER";
	text-align:justify;
	line-height:200%;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
@page Section1
	{size:8.5in 11.0in;
	mso-header-
	mso-footer-
	mso-page-numbers:1;
	mso-title-page:yes;
	mso-even-header: url() eh1;
	mso-header: url() h1;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
@list l0
	{mso-list-id:-131;
	mso-list-type:simple;
	mso-list-template-ids:1265521074;}
@list l0:level1
	{mso-level-tab-stop:60.45pt;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l1
	{mso-list-id:248387907;
	mso-list-template-ids:-853636652;}
@list l1:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level2
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:.5in;}
@list l1:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2
	{mso-list-id:339309350;
	mso-list-template-ids:-1534701368;}
@list l2:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:.5in;}
@list l2:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l3
	{mso-list-id:388502664;
	mso-list-type:simple;
	mso-list-template-ids:-1467875128;}
@list l3:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-3.5in;
	font-family:Symbol;}
@list l4
	{mso-list-id:527061025;
	mso-list-template-ids:2061530658;}
@list l4:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l4:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l4:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l4:level4
	{mso-level-reset-level:level1;
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l4:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l4:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l4:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l4:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l4:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5
	{mso-list-id:727992645;
	mso-list-template-ids:-1413452760;}
@list l5:level1
	{mso-level-start-at:6;
	mso-level-style-link:"heading\: NUMBER";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l5:level2
	{mso-level-reset-level:level1;
	mso-level-style-link:"heading\: NUMBER";
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;
	mso-ansi-font-size:13.0pt;
	font-family:"Times New Roman";
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;}
@list l5:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:.5in;}
@list l5:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6
	{mso-list-id:734011220;
	mso-list-template-ids:486683052;}
@list l6:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-style-link:Normal;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level4
	{mso-level-reset-level:level1;
	mso-level-style-link:Normal;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:.5in;}
@list l6:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l7
	{mso-list-id:764231896;
	mso-list-template-ids:1352008676;}
@list l7:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l7:level2
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l7:level3
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"%3\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l7:level4
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%4\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l7:level5
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l7:level6
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l7:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l7:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l7:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l8
	{mso-list-id:890728182;
	mso-list-type:simple;
	mso-list-template-ids:-940518988;}
@list l8:level1
	{mso-level-text:"\[%1\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;}
@list l9
	{mso-list-id:911693226;
	mso-list-type:simple;
	mso-list-template-ids:67698703;}
@list l9:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l10
	{mso-list-id:1041132961;
	mso-list-type:simple;
	mso-list-template-ids:67698703;}
@list l10:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l11
	{mso-list-id:1135607938;
	mso-list-type:simple;
	mso-list-template-ids:1707907966;}
@list l11:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-weight:bold;}
@list l12
	{mso-list-id:1236354383;
	mso-list-type:simple;
	mso-list-template-ids:-225288742;}
@list l12:level1
	{mso-level-text:"\[%1\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;}
@list l13
	{mso-list-id:1250120100;
	mso-list-template-ids:-2020592624;
	mso-list-name:QUOTE;}
@list l13:level1
	{mso-level-number-format:none;
	mso-level-text:"";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13:level2
	{mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13:level3
	{mso-level-number-format:none;
	mso-level-text:%3;
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13:level4
	{mso-level-suffix:none;
	mso-level-text:"\(%4\)\0009";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l13:level5
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%5\)\0009";
	mso-level-tab-stop:2.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:1.75in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l13:level7
	{mso-level-tab-stop:1.75in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l13:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l13:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l14
	{mso-list-id:1296107855;
	mso-list-type:simple;
	mso-list-template-ids:-1612034996;}
@list l14:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l15
	{mso-list-id:1315601249;
	mso-list-type:simple;
	mso-list-template-ids:-52672024;}
@list l15:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l16
	{mso-list-id:1383941449;
	mso-list-type:simple;
	mso-list-template-ids:67698703;}
@list l16:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l17
	{mso-list-id:1509170297;
	mso-list-template-ids:-1137539842;}
@list l17:level1
	{mso-level-text:"\[%1\]     ";
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l17:level2
	{mso-level-number-format:none;
	mso-level-text:%2;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l17:level3
	{mso-level-number-format:alpha-lower;
	mso-level-text:"%3\)";
	mso-level-tab-stop:.9in;
	mso-level-number-position:left;
	text-indent:-.4in;}
@list l17:level4
	{mso-level-text:"%4\)";
	mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l17:level5
	{mso-level-text:%5;
	mso-level-tab-stop:0in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l17:level6
	{mso-level-text:%6;
	mso-level-tab-stop:0in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l17:level7
	{mso-level-text:%7;
	mso-level-tab-stop:0in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l17:level8
	{mso-level-text:%8;
	mso-level-tab-stop:0in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l17:level9
	{mso-level-start-at:0;
	mso-level-text:"";
	mso-level-tab-stop:0in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18
	{mso-list-id:1550385919;
	mso-list-template-ids:821708086;}
@list l18:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19
	{mso-list-id:1665664019;
	mso-list-template-ids:-1754337048;}
@list l19:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20
	{mso-list-id:1682200304;
	mso-list-template-ids:426402662;}
@list l20:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:.5in;}
@list l20:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l21
	{mso-list-id:1782457026;
	mso-list-type:simple;
	mso-list-template-ids:1131831968;}
@list l21:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l22
	{mso-list-id:1785883979;
	mso-list-template-ids:1689811090;}
@list l22:level1
	{mso-level-number-format:alpha-lower;
	mso-level-text:"\(%1\)";
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l22:level2
	{mso-level-number-format:none;
	mso-level-text:%2;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l22:level3
	{mso-level-number-format:alpha-lower;
	mso-level-text:"\(%3\)";
	mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22:level4
	{mso-level-number-format:none;
	mso-level-text:"\(i\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:.5in;}
@list l22:level5
	{mso-level-text:%5;
	mso-level-tab-stop:0in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22:level6
	{mso-level-text:%6;
	mso-level-tab-stop:0in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22:level7
	{mso-level-text:%7;
	mso-level-tab-stop:0in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22:level8
	{mso-level-text:%8;
	mso-level-tab-stop:0in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22:level9
	{mso-level-start-at:0;
	mso-level-text:"";
	mso-level-tab-stop:0in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l23
	{mso-list-id:1816682448;
	mso-list-template-ids:-784801062;}
@list l23:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l23:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l23:level3
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-text:"%3\)";
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l23:level4
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%4\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l23:level5
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l23:level6
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l23:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l23:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l23:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l24
	{mso-list-id:1860773060;
	mso-list-type:simple;
	mso-list-template-ids:1515980402;}
@list l24:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-weight:bold;}
@list l25
	{mso-list-id:1869180514;
	mso-list-template-ids:-1483452776;}
@list l25:level1
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%1\)";
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l25:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:"\(%2\)";
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l25:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%3\)";
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l25:level4
	{mso-level-text:"\(%4\)";
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l25:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l25:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l25:level7
	{mso-level-tab-stop:1.75in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l25:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l25:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:2.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l26
	{mso-list-id:2059817004;
	mso-list-template-ids:-1213419456;}
@list l26:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l26:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l26:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l26:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l26:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l26:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l26:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l26:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l26:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l27
	{mso-list-id:2077392087;
	mso-list-type:simple;
	mso-list-template-ids:67698703;}
@list l27:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
ol
	{ul
	{-->
</style>
</head>
<body bgcolor="#FFFFFF" style='tab-interval:.5in' lang=EN-CA>
<div class=Section1> 
  <h5>DATE:<span style="mso-spacerun: yes">  </span>20050916<br>
    <b style='mso-bidi-font-weight:
normal'>DOCKET: <u>C42177<br>
    </u></b><u><span style='mso-bidi-font-weight:bold'>C42169</span></u></h5>
  <h2>COURT OF APPEAL FOR ONTARIO</h2>
  <h4 align=center style='text-align:center'><span lang=EN-US>LABROSSE, SHARPE 
    and ROULEAU JJ.A.</span></h4>
  <table border=0 align="center" cellpadding=0 cellspacing=0 style='border-collapse:collapse;
 mso-padding-alt:0in 5.4pt 0in 5.4pt'>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>B E T W E E 
          N :</b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>MINISTER OF 
          HEALTH AND LONG-TERM CARE (ONTARIO), LIEUTENANT GOVERNOR IN COUNCIL 
          and ATTORNEY GENERAL OF ONTARIO<br>
          Appellants (Respondents) </b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Dennis W. Brown 
          Q.C., John Zarudny, James Kendik for the Minister</b></p>
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Earl A. Cherniak 
          Q.C. and David D. Conklin for Genpharm </b></p></td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>- and -</b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal>&nbsp;</p></td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>APOTEX INC.<br>
          </b><b style='mso-bidi-font-weight:normal'>COBALT PHARMACEUTICALS<br>
          </b><b style='mso-bidi-font-weight:normal'>PHARMASCIENCE INC.<br>
          </b><b style='mso-bidi-font-weight:normal'>RHOXALPHARMA INC.<br>
          Respondents (Applicants) </b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Harry Radomski 
          and Joseph Cosentino for Apotex Inc.</b></p>
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Carol Hitchman 
          for RhoxalPharma Inc. and PharmaScience Inc.</b></p>
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Lawrence Thacker 
          and Dena Varah<br>
          For Cobalt Pharmaceuticals Inc. </b></p></td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
    </tr>
    <tr> 
      <td valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>-and- 
          </b></p></td>
      <td valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
      <td valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>GENPAHARM 
          INC<br>
          </b><b style='mso-bidi-font-weight:
  normal'>Appellant (Intervenor)</b></p></td>
      <td valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td colspan="2" valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td colspan="2" valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Heard:<span
  style="mso-spacerun: yes">  </span>September 12 and 13, 2005</b></p></td>
    </tr>
  </table>
  <p class=MsoBodyText>On appeal from the judgment of Justice John G.J. O'Driscoll 
    of the Superior Court of Justice, sitting as a judge of the Divisional Court, 
    dated April 27, 2004.</p>
  <h4 align=left style='text-align:left;line-height:normal'><span lang=EN-US>BY 
    THE COURT:</span></h4>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[1]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> T<span lang=EN-US style='mso-ansi-language:EN-US'>he appellant 
    Genpharm Inc. and the respondents Apotex Inc., Cobalt Pharmaceuticals Inc., 
    Pharmascience Inc., and Rhoxalpharma Inc. are manufacturers and distributors 
    of pharmaceutical products.<span style="mso-spacerun: yes">  </span>This appeal 
    arises from a contest among these five generic drug companies to become the 
    first to have a new generic drug, citalopram, listed on the Ontario Drug Benefit 
    Formulary/Comparative Drug Index (the “Formulary”).<span style="mso-spacerun: yes">  
    </span>The winner of this race would reap substantial benefits.<span style="mso-spacerun: yes">  
    </span></span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[2]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>When it appeared 
    that Genpharm had won the race, the respondents applied for judicial review, 
    challenging the fairness of the process.<span
style="mso-spacerun: yes">  </span>Although not named as a party or served with 
    the application, Genpharm appeared and was granted intervenor status. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[3]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>The application 
    judge granted judicial review, nullified Genpharm’s apparent success in being 
    the first to be listed, and set in motion a process whereby the products of 
    all five manufacturers were simultaneously listed.</span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[4]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>Genpharm and 
    The Minister of Health and Long-Term Care (Ontario), Lieutenant Governor in 
    Council and Attorney General of Ontario (the “Minister”) both appeal the decision 
    of O’Driscoll J., sitting as a single judge of the Divisional Court pursuant 
    to subsection 6(2) of the <i>Judicial Review Procedure Act, </i>R.S.O. 1990, 
    c.J.1, quashing the extension of a cut-off date for completion of drug submissions 
    regarding an update to the Formulary. </span></p>
  <h4 align=left style='text-align:left;line-height:normal'><span lang=EN-US>FACTS</span></h4>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[5]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>Before a generic 
    drug is listed on the Formulary, its manufacturer must apply to the Minister 
    under the <em>Drug Interchangeability and Dispensing Fee Act</em> R.S.O. 1990 
    c. P. 23 (<em>DIDFA</em>) to have the drug approved as “interchangeable” with 
    a named drug. In the application, the drug company must show that the drug 
    has been approved for sale in Canada by the federal government by including 
    with the application a “Notice of Compliance” issued by federal authorities 
    to the effect that the drug is safe. Until recently, the Formulary took the 
    form of a regulation enacted by the Lieutenant Governor in.</span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[6]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>At the time 
    the five drug companies were working to have their brand of citalopram listed 
    on the Formulary, the Minister announced a November 30, 2003 deadline (the 
    “cut-off date”) for the drug companies to file any applications for approval 
    under the <i>DIDFA.</i><span style="mso-spacerun: yes">  </span>That deadline 
    was geared to an expected Cabinet meeting.<span style="mso-spacerun:
yes">  </span>None of the parties had filed a complete application by that deadline.<span style="mso-spacerun: yes">  
    </span>When the date for the expected Cabinet meeting shifted, the Minister 
    extended the deadline to December 31, 2003, without notice to anyone outside 
    the Ministry. By that deadline, Genpharm had received its Notice of Compliance 
    and had filed its application for approval.<span style="mso-spacerun: yes">  
    </span>The only outstanding matter in Genpharm’s application was confirmation 
    of the price it would charge for the drug. None of the respondents had received 
    their Notices of Compliance by the extended deadline.<span style="mso-spacerun: yes">  
    </span>After the extended deadline, Genpharm confirmed the price and the Minister 
    forwarded Genpharm’s application to the Cabinet for approval.<span
style="mso-spacerun: yes">  </span>Approval was given and Genpharm’s product was 
    listed in the Formulary to come into effect on April 6, 2004. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[7]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>It is common 
    ground that, had the Formulary come into effect on that date, Genpharm would 
    have secured significant competitive advantages and monetary benefits from 
    being the first manufacturer to have the drug listed on the Formulary. </span></p>
  <h4 align=left style='text-align:left;line-height:normal'><span lang=EN-US>THE 
    APPLICATION FOR JUDICIAL REVIEW</span></h4>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[8]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>The respondents 
    commenced urgent applications for judicial review, returnable April 2, 2004, 
    arguing that the extension of the deadline had given Genpharm an unfair advantage.<span style="mso-spacerun: yes">  
    </span>For reasons we fail to understand, Genpharm was not named as a party, 
    nor was it served with the applications for judicial review, despite the fact 
    that its interests were clearly implicated by the application for judicial 
    review.<span
style="mso-spacerun: yes">  </span>However, a lawyer representing Genpharm was 
    present in court on April 2. Counsel requested an adjournment to permit her 
    client to review the application and, if advised, seek intervenor status.<span
style="mso-spacerun: yes">  </span>The application judge granted the adjournment 
    to April 5 and made an interim order restraining the Minister from implementing 
    the proposed April 6 Formulary until further order.</span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[9]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>On April 5, 
    two counsel for Genpharm appeared and asked to be granted intervenor status.<span style="mso-spacerun: yes">  
    </span>The request, not opposed by the respondents, was granted. Presumably 
    on Genpharm’s instructions, counsel did not request a further adjournment 
    but indicated that they were prepared to argue the matter on their client’s 
    behalf.<span style="mso-spacerun: yes">  </span>After a full day of argument, 
    judgment was reserved.<span
style="mso-spacerun: yes">  </span>There was no alteration of the interim order 
    of April 2 and accordingly it continued in effect until April 27 when the 
    application judge released his judgment granting the application for judicial 
    review. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[10]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>On April 6, 
    counsel for Genpharm wrote to inform the application judge that he intended 
    to bring a motion to set aside the April 2 order, to cross-examine the deponents 
    of the affidavits filed in support of the application for judicial review, 
    to adduce further evidence, and to reopen the hearing.<span
style="mso-spacerun: yes">  </span>Genpharm now took the position that it had 
    not received proper notice or been given a proper opportunity to present its 
    case.<span style="mso-spacerun: yes">  </span>Counsel sent the motion to the 
    application judge on April 8 requesting a hearing date.<span
style="mso-spacerun: yes">  </span>The application judge did not respond and Genpharm’s 
    counsel wrote two further letters requesting a date for the hearing of the 
    motion. Again, the application judge did not respond. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[11]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>In his April 
    27 reasons granting the application for judicial review, the application judge 
    stated:</span></p>
  <p class=Doubleindent-quote align=left style='text-align:left'>In my view, by 
    any method of measurement, the words and actions of the [Minister] in moving 
    the goal posts and the yardsticks during the course of the competition, and 
    in doing so without notice to the competitors, produced a procedurally unfair 
    contest. </p>
  <p class=MsoNormal align=left style='text-align:left'><span lang=EN-US
style='mso-ansi-language:EN-US'>As for the motion to reopen the hearing, hold 
    cross-examinations and adduce further evidence, the application judge stated: 
    </span></p>
  <p class=Doubleindent-quote align=left style='text-align:left'>Because my decision 
    has its roots in what Ministry officials advised, said and did both in and 
    out of office of the Ministry… about the November 30, 2003 cut-off date, I 
    saw no injustice or inequity in proceeding with the record as it existed on 
    April 5, 2004</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[12]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>The order 
    for judicial review continued the interim order of April 2 enjoining the Minister 
    from implementing the proposed April 6 Formulary and required the Minister 
    to establish a new “drop-dead - cut-off date” for completion of submissions 
    to allow all interested parties reasonable time to make their submissions. 
    Genpharm served a motion for leave to appeal and a motion for a stay but did 
    not proceed with the stay motion.</span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[13]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>The Minister 
    complied with both the interim and final orders of the application judge, 
    setting a new cut-off date. In July 2004, the citalopram products of all five 
    companies were approved and put on the market. </span></p>
  <p class=MsoSubtitle style='line-height:normal'><span lang=EN-US
style='font-size:13.0pt'>MOOTNESS</span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [14]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> At the outset of oral argument, we indicated to counsel that before 
    entertaining submissions on the substance of the appeal we wished to hear 
    from them on the issue of mootness. After hearing submissions on that issue, 
    we reserved our decision on mootness and heard Mr. Cherniak and Mr. Conklin 
    on the merits of Genpharm’s appeal. </p>
  <p class=MsoSubtitle style='line-height:normal'><span lang=EN-US>THE MINISTER’S 
    APPEAL</span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[15]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-bidi-font-size:13.0pt;
mso-ansi-language:EN-US'>We have concluded that the Minister’s appeal should be 
    dismissed as moot.<span style="mso-spacerun: yes">  </span>The </span><span
lang=EN-US style='mso-ansi-language:EN-US'>Minister’s appeal raises three issues: 
    (1) whether the process regarding drug submissions is subject to judicial 
    review; (2) whether the application judge erred in deciding that the Minister’s 
    actions were patently unreasonable; and (3) whether, by ordering the Minister 
    to set and adhere to a new cut-off date, the application judge wrongly interfered 
    with internal government processes. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[16]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>As already 
    indicated, in July 2004, the Minister published a new Formulary which included 
    the products of all five drug companies.<span style="mso-spacerun:
yes">  </span>Both the interim decision and final decision of the application 
    judge have been complied with and have no continuing application.<span
style="mso-spacerun: yes">  </span>In our view, even if the Minister were successful 
    on the appeal, the result could not now have any practical effect on the rights 
    of the parties.<span style="mso-spacerun: yes">  </span>All the parties have 
    now complied with the requirements for having their drugs listed.<span
style="mso-spacerun: yes">  </span>If the order for judicial review were now set 
    aside, they would still all be entitled to be listed in the Formulary. Allowing 
    the appeal would achieve nothing.<span style="mso-spacerun: yes">  </span>As 
    the issue cannot now be revisited and a decision of this court will not have 
    the effect of resolving some controversy which affects or may affect the rights 
    of the parties, the Minister’s appeal is moot:<span
style="mso-spacerun: yes">  </span>see <i>Borowski v. Canada (Attorney General), 
    </i>[1989] 1 S.C.R. 342 at 353. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[17]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-bidi-font-size:13.0pt;
mso-ansi-language:EN-US'>Nor are there outstanding issues of law that should be 
    resolved at this time.<span style="mso-spacerun: yes">  </span></span><span
lang=EN-US style='mso-ansi-language:EN-US'>Until recently, the approval process 
    for generic drugs in Ontario under the <i>DIDFA</i> was very complicated.<span
style="mso-spacerun: yes">  </span>A generic drug application was reviewed by 
    several levels of bureaucracy as well as two Cabinet committees.<span
style="mso-spacerun: yes">  </span>Internal deadlines for drug approvals were 
    set by Ministry officials, but as this case indicates, these deadlines would 
    change as Cabinet priorities shifted.<span style="mso-spacerun: yes">  </span>Often 
    the deadlines were not publicized, and in fact were sometimes considered to 
    be confidential.<span style="mso-spacerun: yes">  </span></span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[18]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>In June 2004, 
    the Minister issued new guidelines for drug submissions which are now published 
    on its website, intended to provide “more transparency” and to provide “more 
    guidance” for generic manufacturers.<span style="mso-spacerun:
yes">  </span>Moreover, the decision process has been greatly simplified and the 
    decision is now made by the Minister instead of Cabinet, removing any question 
    as to the availability of judicial review.<span style="mso-spacerun:
yes">  </span>Accordingly, deciding this appeal would be of little assistance 
    to the Minister or to future applicants seeking generic drug approval in resolving 
    legal issues. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[19]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>The Minister’s 
    appeal would have no practical effect on the rights of the parties and, as 
    the legal landscape has changed, there are no outstanding issues that we should 
    resolve.<span style="mso-spacerun: yes">  </span>Accordingly, we decline to 
    entertain the Minister’s appeal on the ground that it is moot.</span></p>
  <h4 align=left style='text-align:left;line-height:normal'><span lang=EN-US>GENPHARM’S 
    APPEAL</span></h4>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[20]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>In addition 
    to the issues raised by the Minister, Genpharm submits that the application 
    judge denied it natural justice by refusing to entertain the motion to reopen 
    the case.</span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[21]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>In support 
    of its submission that the appeal is not moot, Genpharm argues that, should 
    it be successful in this appeal, it will have a viable cause of action against 
    the respondents.<span style="mso-spacerun: yes">  </span>In its factum, that 
    action was identified as one for damages based on intentional interference 
    with economic interests and abuse of process.<span style="mso-spacerun: yes">  
    </span>In oral argument, reference was also made to an action in conspiracy.<span style="mso-spacerun: yes">  
    </span>If the order of the application judge stands, Genpharm is concerned 
    that the respondents will be able to argue that such action is a collateral 
    attack on the order.<span
style="mso-spacerun: yes">  </span>Therefore, argues Genpharm, there remains a 
    live dispute between the parties and this appeal is not moot.</span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[22]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>In our view, 
    Genpharm’s appeal is moot.<span style="mso-spacerun: yes">  </span>Further, 
    we are not persuaded that we should exercise our discretion to entertain the 
    appeal.<span style="mso-spacerun: yes">  </span></span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[23]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>First, with 
    respect to the proposed claim in conspiracy, Mr. Radomski, speaking after 
    consultation with and on behalf of all respondents’ counsel, conceded that 
    the respondents would not raise the doctrine of collateral attack as a defence 
    against a properly pleaded claim of conspiracy. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[24]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-bidi-font-size:13.0pt;
mso-ansi-language:EN-US'>Second, with respect to the claim for intentional interference 
    with economic relations and abuse of process, </span><span
lang=EN-US style='mso-ansi-language:EN-US'>Genpharm has simply not provided us 
    with a sufficient basis to assess whether its intended action has any prospect 
    of success.<span style="mso-spacerun: yes">  </span></span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[25]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>To be successful 
    in such a claim, Genpharm would have to overcome several substantial hurdles.<span style="mso-spacerun: yes">  
    </span>In their factums, the respondents relied on past jurisprudence to argue 
    that a claim for intentional interference with economic relations or abuse 
    of process could not succeed in law. Genpharm provided us with no answer to 
    those submissions.<span
style="mso-spacerun: yes">  </span>The grounds for this proposed action remain 
    sketchy at best.<span style="mso-spacerun: yes">  </span>Although more than 
    eighteen months have passed, Genpharm has not commenced any action, nor were 
    we provided with a draft statement of claim that would enable us to assess 
    the viability of such a claim. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[26]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>The ingredients 
    for an action for abuse of process are well established.<span
style="mso-spacerun: yes">  </span>In <i>Metrick v. Deeb</i> </span>(2003), 172 
    O.A.C. 229, <span lang=EN-US style='mso-ansi-language:EN-US'>this court adopted 
    the test from <i>Fleming on Torts</i> 4<sup>th</sup> ed, (1971) at 548:</span></p>
  <p class=Doubleindent-quote align=left style='text-align:left'>The essential 
    elements of abuse of process are: first, a collateral and improper purpose, 
    such as extortion, and secondly, a definite act or threat, in furtherance 
    of a purpose not legitimate in the use of the process.<span style="mso-spacerun:
yes">  </span>Some such overt conduct is essential, because there is clearly no 
    liability when the defendant merely employs regular legal process to its proper 
    conclusion, albeit with bad intentions.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[27]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>Did the actions 
    of the respondents, aimed at the fairness of the process that led to the proposed 
    April 6 Formulary, have a “collateral or improper purpose”?<span style="mso-spacerun: yes">  
    </span>The respondents were certainly trying to advance their own economic 
    interests at the expense of the interests of Genpharm, but that is hardly 
    unusual in this type of litigation. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[28]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>Another hurdle 
    faced by Genpharm in bringing an action against the respondents is that the 
    damages Genpharm suffered resulted directly from the order for judicial review. 
    We were referred to no case, apart from claims on undertakings for damages 
    on interlocutory injunctions, standing for the proposition that an action 
    for damages occasioned by an erroneous order of a superior court, even orders 
    made without proper notice, can succeed. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[29]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>Third, even 
    if the proposed action for abuse of process or intentional interference with 
    economic relations is viable, we have not been persuaded that it would necessarily 
    be defeated by the doctrine of collateral attack. We were given no authority 
    on the issue of collateral attack.<span style="mso-spacerun: yes">  </span>We 
    nevertheless note that the Supreme Court of Canada has held the doctrines 
    of collateral attack and issue estoppel to be discretionary in nature, especially 
    where a party can show that it was denied the right to a fair hearing: see 
    <i>Danyluk</i> <i>v. Ainsworth Technologies Inc.</i>, [2001] 2 S.C.R. 460 
    at para. 80. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[30]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>Fourth, Genpharm’s 
    conduct is hardly consistent with the assertion that it has been the victim 
    of a gross violation of natural justice.<span style="mso-spacerun:
yes">  </span>As we have noted, counsel appeared on April 2 and was granted an 
    adjournment.<span style="mso-spacerun: yes">  </span>On April 5, Genpharm 
    was granted intervenor status, and confirmed that it was ready to proceed 
    and to argue the appeal without asking for a further adjournment.<span
style="mso-spacerun: yes">  </span>The motion to reopen the case and introduce 
    fresh evidence was brought after the conclusion of argument. Genpharm took 
    no steps to appeal the interim order and did not proceed with its motion for 
    a stay the final order, or ask for an expedited appeal.</span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[31]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>Fifth, as 
    a practical matter, on the basis of the record before us it would be impossible 
    for this court to resolve several contested issues of fact upon which Genpharm’s 
    appeal turns. In particular, we refer to the evidence Genpharm sought to introduce 
    after the hearing: (1) disputing assertions by the respondents, including 
    a representation made to the application judge on April 2, that Genpharm knew 
    of the application for judicial review, and (2) that even if the respondents 
    had known of the revised deadline, that would have had no impact on the processing 
    of their applications. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[32]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>If we were 
    to accept Genpharm’s argument that it was improperly thwarted in presenting 
    all the relevant facts and allow the appeal, it is difficult to see how we 
    could avoid sending the case back for a fresh hearing.<span
style="mso-spacerun: yes">  </span>We would, in effect, be ordering the Divisional 
    Court to rehear the application despite the fact that what has been done cannot 
    now be undone.<span style="mso-spacerun: yes">  </span>As the application 
    for judicial review cannot now be unscrambled, it seems wrong to us to entertain 
    an appeal that would lead us to order a rehearing and the consequent development 
    of a new record, for the collateral purpose of allowing Genpharm to clear 
    the ground for its proposed damages action. </span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[33]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>Taking all 
    of these factors into account, we are satisfied that this appeal should be 
    dismissed as moot.<span style="mso-spacerun: yes">  </span>We are being asked 
    to decide this appeal on the merits for the sole purpose of removing a possible 
    impediment to a proposed action, the details of which remain sketchy and the 
    underlying facts of which are undetermined.<span style="mso-spacerun: yes">  
    </span>The respondents concede that they would not raise the doctrine of collateral 
    attack in defence to a properly pleaded conspiracy action.<span
style="mso-spacerun: yes">  </span>As to the other contemplated claims, assuming 
    they are viable and proceeded with and that the doctrine of collateral attack 
    can be raised in defence to them, that doctrine is discretionary and allows 
    for relief where a party can show the denial of a fair hearing.<span
style="mso-spacerun: yes">  </span></span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [34]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> <span lang=EN-US style='mso-ansi-language:EN-US'>Accordingly, the 
    appeal is dismissed as moot and we decline to consider it on the merits. The 
    respondents are entitled to their costs. We do not agree that the costs should 
    be assessed on the reduced basis of what might have been incurred had the 
    matter been dealt with by way of a motion to quash. That argument aside, the 
    parties agree that Apotex’s costs should be assessed on a partial indemnity 
    basis at $40,000 inclusive of GST and disbursements, and Rhoxalpharma and 
    Pharmascience’s costs should be assessed on a partial indemnity basis at $15,000 
    plus GST and disbursements. While we do not doubt the hours submitted by Mr. 
    Thacker, we agree that in view of the fact that Apotex assumed the lead on 
    this appeal, the appellants cannot reasonably be expected to pay his client, 
    Cobalt Pharmaceuticals, more than $15,000 plus GST and disbursements, the 
    amount agreed to be paid by Rhoxalpharma and Pharmascience.</span></p>
  <p class=MsoNormal align=right style='text-align:right'>“J-M. Labrosse J.A.”</p>
  <p class=MsoNormal align=right style='text-align:right'>“Robert J. Sharpe J.A.”</p>
  <p class=MsoNormal align=right style='text-align:right'>“Paul S. Rouleau J.A.”</p>
  <h4 align=left style='text-align:left;line-height:normal'><span lang=EN-US>RELEASED:<span
style="mso-spacerun: yes">  </span>September 16, 2005</span></h4>
</div>
</body>
</html>
